.
91
Phlorotannins, and more commonly brown seaweed extracts, beneficially effect a range of 92 biological processes including modulation of inflammation; reduction of oxidative stress and 93 improvement in cardiovascular function (9) (10) (11) . However, the evidence base depends heavily 94 upon cell and small animal models with few studies involving humans (12) (13) Ascophyllum nodosum is of interest as it is one of only a few commercially sustainable seaweed 98 species.
99
Phlorotannin-rich extracts from brown seaweeds have been shown to be effective in 100 controlling inflammation via a number of pathways including inhibition of pro-inflammatory 101 cytokines including tumour necrosis factor (TNF)-α and interleukins (IL)-1β and IL-6 (14) .
102
Extracts from Ascophyllum nodosum and other Fucoid species have shown efficacy in 103 mitigating the effects of oxidative stress by playing an inhibitory role in the generation of
Preparation of food-grade seaweed extracts and capsule

126
A novel (poly)phenol-rich seaweed extract from Ascophyllum nodosum was produced by and LC-MS analysis and has been reported previously (20) (see supplemental figure 2 & 3).
144
Phlorotannins were quantified using the Folin-Ciocalteau Method (22) using phloroglucinol as 145 the standard. In brief, 1 mL of suitability diluted sample was reacted with 1.00 mL of 40 %
146
Folin Ciocalteu reagent for 5 min, and then made alkaline with the addition of 1.00 ml of 100 147 g/L Na2CO3. 
Study design
166
The study was a 24-week randomised, double-blind, placebo-controlled crossover trial.
167
After obtaining consent, participants were randomly assigned, in blocks of four using a 168 random-number generator (www.randomization.com), to either the intervention or the control.
169
In total, eighty participants were randomised to 2 groups of 40, each starting on either a 400 170 mg seaweed (poly)phenol extract (SPE) capsule containing 100mg of (poly)phenols or a 400 171 mg maltodextrin placebo control capsule (Avebe MD14P) daily for an 8-week period. The 172 participants were supplied with all capsules in weekly labelled capsule boxes at the beginning 173 of each phase, which was interspersed by an 8-week washout phase. During the washout phase, 174 the participants were asked to maintain their habitual diet. Participants were asked to bring any 175 unconsumed capsules to their study appointment at the end of each treatment phase.
176
Participants were also contacted weekly by the study researcher to encourage compliance and 177 to discuss any difficulties they were experiencing. Processing of urine and plasma.
263
Urine samples were defrosted, vortexed, centrifuged at 16110 g for 10 min at 5 °C, and 264 passed through 0.45 μm filter discs prior to the analysis of 50 μL aliquots by UHPLC-HR-MS.
265
The extraction of metabolites from the plasma samples has been carried out as described 266 previously (28) . Briefly, plasma samples were defrosted, vortexed and 400 µL aliquots were 267 mixed with 10 µL of ascorbic acid (10%, v/v), and 980 µL of 1% formic acid in acetonitrile.
268
One µg of rutin was added to the samples as internal standard for plasma extraction efficiency.
269
The samples were then vortexed for 1 min and ultrasonicated for 10 min. After centrifugation Non-targeted analysis of urine and plasma by UHPLC-HR-MS.
277
Aliquots of selected plasma and urine samples were analysed using a Dionex Ultimate 3000
278
RS UHPLC system comprising of a UHPLC pump, a PDA detector scanning from 200 to 600 nm, and an autosampler operating at 4 °C (Thermo Scientific). The HPLC conditions were and processing were carried out using Xcalibur 3.0 software.
291
Untargeted analysis of the selected urine and plasma samples was performed using mass previous studies (15, 20 was not significantly different by treatment group or time period (P>0.05) (Figure 1 ). There
361
were no significant differences between the participants in age and physical characteristics at 362 the beginning of either treatment phase ( Table 2) .
364
Habitual dietary intake
365
Dietary analysis of habitual intake (midpoint) during both treatment phases (SPE,
366
Maltodextrin) of the crossover trial is described in Table 3 . There were no significant Maltodextrin) for all of the participants (n=78), in the overweight participants (n=42) or in the 406 obese participants (n=36) (Figure 4) . Nor where significant effects observed in the cytokine class of interest correctly assigned to their class) and 100% and 100% specificity (participants 427 not belonging to the class of interest were correctly not assigned to that class), respectively (Supplemental Figure 1) supervised OPLS-DA models were built to discriminate according to the seaweed treatment in 437 both models ( Figure 5 ). In our study we used two latent variables (LV) and the sensitivity and 438 specificity values were set to 100% at the calibration step recognition ability of the two models.
439
These analyses showed that the human urine metabolome in both groups of participants was The main contributors to metabolome differentiation in the urine before and after seaweed 451 consumption in both groups of participants are described in Supplemental Table 1 and Table 2 452 (Table 5) .
462
Based upon the identified seaweed (poly)phenol metabolites, the total amount of seaweed total seaweed metabolites concentrations >2 mmoles (see Supplemental Table 6 ).
469
The plasma metabolome demonstrated no clear differentiation for participants in either 470 treatment phase (data not shown), nor with exploration of the data by PCA or HCA.
471
Consequently no exposure biomarkers could be defined for plasma samples taking into account 472 all the participants (n=78). 
DISCUSSION
475
The association of seaweed consumption with reduced risk factors for CVD has been tested 476 largely within in vitro or animal models, and only limited human data exists to substantiate the proposed beneficial properties of seaweeds (12, 13, 34 we similarly observed no significant changes in IL-2 or TNF, nor did we see an alteration in (poly)phenols such as orange juice, cranberry and pomegranate (48) (49) (50) .
536
The results from the non-targeted approach confirmed the presence of seaweed phenolic inter-individual variation in gut microbiota underlie these metabolic changes and were 551 responsible for the observed differences. That said, the study of bioavailability of seaweed (Wilcoxin signed rank test). 4 Mean ± SD. 5 Calculated using the Englyst method. 
FIGURE 2.
Comparison of the effects of SPE supplementation phase () with that of a placebo phase () on total oxidative capacity (TOC) in the total study population (n=78), in overweight (n=42), and in obese (n=36). All values were measured in duplicate expressed as mean ± SD.
TOC is represented as the mean of the individual difference values (after -before supplementation) in the SPE and placebo treatment phases. 2. The cut off VIP value selected to be 2. For VIP scores identification see Table 5 and Supplemental 
Control phase (n=39)
Placebo capsule 1 x 400mg/day for 8 weeks
Intervention phase (n=39)
Seaweed capsule 1 x 400mg/day for 8 weeks 
